Moreover, treatment of WT, but not FXR KO mice, with an FXR agonist could protect against intestinal inflammation, demonstrating that FXR activation protects against the development of intestinal inflammation in murine models of inflammatory bowel disease [46,71]. Here, NR1H4 is linked to inflammatory bowel disease.